SEC Form 4 · accession 0001672659-26-000033
Mineralys Therapeutics, Inc. · MLYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Malcom Rodman
Officer — Chief Medical Officer
Period of report
Jul 9, 2026
Accepted (ET)
Jul 10, 2026 · 7:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001933414
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 9, 2026 | M | 2,171 | $16.00 | A | 59,904 | D | |
| Common Stock | Jul 9, 2026 | S | 2,171 | $30.30 | D | 57,733 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3 | $16.00 | Jul 9, 2026 | M | 2,171 | D | — | Feb 9, 2033 | Common Stock | 2,171 | 15,194 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
- F2This balance includes 638 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
- F3The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.